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Abstract: This paper reports the experimental assessment of an automated optical assay 
based on label free optical fiber optrodes for the fast detection of class C β-lactamases (AmpC 
BLs), actually considered as one of the most important sources of resistance to β-lactams 
antibiotics expressed by resistant bacteria. Reflection-type long period fiber gratings (RT-
LPG) have been used as highly sensitive label free optrodes, while a higher affine boronic 
acid-based ligand was here selected to enhance the overall assay performances compared to 
those obtained in our first demonstration. In order to prove the feasibility analysis towards a 
fully automated optical assay, an engineered system was developed to simultaneously 
manipulate and interrogate multiple fiber optic optrodes in the different phases of the assay. 
The automated system tested in AmpC solutions at increasing concentrations demonstrated a 
limit of detection (LOD) of 6 nM, three times better when compared with the results obtained 
in our previous work. Moreover, the real effectiveness of the proposed optical assay has been 
also confirmed in complex matrices as the case of lysates of Escherichia coli overexpressing 
AmpC. 
© 2017 Optical Society of America 
OCIS codes: (280.1415) Biological sensing and sensors; (060.2390) Fiber optic, infrared; (170.4580) Optical 
diagnostics for medicine; (230.4170) Multilayers; (350.2770) Gratings 
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1. Introduction 
The emergence of infections caused by Gram-negative resistant pathogens is rapidly and 
continuously increasing [1–3]. β-lactamases (BLs) are among the most diffuse resistance 
mechanism to β-lactams antibiotics such as penicillins and cephalosporins, being able to 
hydrolyze and consequently inactivate these drugs. For these enzymes β-lactam-based 
inhibitors such as clavulanic acid or sulbactam are ineffective and “β-lactamase stable” β-
lactams, such as ceftazidime, are recognized as substrates. Indeed, some pathogens have 
evolved mechanisms that, in the presence of primary β-lactams or β-lactam-based inhibitor, 
up-regulate the expression of the BLs that they were designed to evade or inhibit. The broad 
activity of class C (AmpC) - BLs and the regulatory response to classic β-lactams has 
motivated a search for novel inhibitors structurally unrelated to β-lactams [4,5]. As 
researchers are struggling to find novel antibiotics and/or BLs inhibitors able to counteract 
resistance, new methods for BLs detection are increasingly necessary. The rapid identification 
of BLs produced by a pathogen and of the relative antibiotic resistance would, in fact, allow 
the administration of the most appropriate therapy and, possibly, the saving of last generation 
drugs, with a positive socio-economic impact on the whole society. The potential benefits of 
having an efficient BL detection system would include reduced hospitalization time, lower 
illness severity, lower treatment failure, and reduction in the escalation of antibiotic resistance 
in clinical settings and in the community. The methodologies currently available for the 
detection of BLs producing bacteria in biological samples generally require bacteria growing 
on Petri plates and resistance marker identification through the use of last generation 
antibiotics, BLs gene identification through PCR techniques or phenotypic approaches [6–
10]. These methods are quite time consuming because of the necessary bacterial growth 
(about 24~48 hours according to the infecting bacteria), they are generally expensive, not 
always sensitive, and they also require trained personnel. 
To overcome these limitations, label-free detection methodologies have been developed, 
since they allow the recognition of target molecules in their natural forms, and they are 
relatively easy and cheap. In this context, different highly sensitive optical probes, able to 
detect unlabeled biomolecules, have been developed [11,12]. Among all, Long Period Fiber 
Gratings (LPGs) are probably the most promising fiber grating technological platforms to be 
employed as label free biosensors, thanks to the intrinsic sensitivity to the surrounding 
refractive index (SRI) changes [11–16]. We recently developed a RT-LPG biosensor for the 
detection of drug resistance infection biomarkers [17]. Specifically, a standard LPG working 
in transmission mode was first transformed in a probe able to work in reflection configuration 
[16], and then coated with two polymeric overlays, atactic polystyrene (aPS) and 
polymethylmetacrylate-co-metacrylic acid (PMMA-co-MA), to maximize the device 
sensitivity in aqueous environments, and to provide the necessary conditions for a correct bio-
functionalization. The well-known AmpC inhibitor 3-aminophenylboronic acid (3-APBA, 
compound 1, Fig. 1) was first used as immobilized ligand on the RT-LPG surface [17], due its 
capability of binding AmpC with micromolar affinity (Ki = 7.3 µM) [18]. AmpC attachment 
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tests on the biofunctionalized RT-LPG surface led to the protein detection at the very low 
concentration of 100 nM, in both purified and complex biological samples. Here we 
investigated the possibility of enhancing the performance of the aforementioned biosensor 
(reducing the LOD with respect to the previous one using 3-APBA) by using a different, more 
affine, boronic acid derivative. Specifically, using both structure-based [19,20] and transition-
state analog approaches, several such novel ligands have been developed. Among the most 
potent of these there is benzo[b]thiophene-2-ylboronic acid (BZB, compound 2, Fig. 1), 
which binds the canonical AmpC BLs with a Ki value of 0.027 μM [4]. More recently, 
Minozzi et al. [21] have identified 5-aminomethylbenzo[b]thiophen-2-boronic acid (BZD, 
compound 3, Fig. 1) as a BZB's derivative with an improved permeability index, better 
solubility and better cell efficacy despite its higher Ki (0.26 μM). 
 
Fig. 1. Chemical structure of the selected AmpC boronic-based inhibitors: (1) 3-aminophenyl 
boronic acid (3-APBA), (2) benzo[b]thiophen-2-yl boronic acid (BZB) and (3) 5-
aminomethylbenzo[b]thiophen-2-ylboronic acid (BZD). 
Hence, among all the low nanomolar ligands developed, we finally decided to select BZD 
as a suitable ligand to fish out AmpC BL. The chemical and physical properties of BZD fulfill 
all the necessary requirements for the present study: the structure of BZD itself resembles that 
of BZB (one of the most known in vivo affine ligands for AmpC BL), the aminomethyl 
moiety in position 5 of its chemical structure behaves as a linker facilitating the binding on 
the double-coated RT-LPG surface. Hence, its solubility in buffer has been enhanced with 
respect to BZB and its inhibition constant (Ki) maintains a low value equal to 0.26 μM [4,21]. 
In this context, to perform simultaneous multi-target clinical analyses, we report the design 
and development of an automated system able to carry out both the immersion of different 
probes in several solutions (buffer, functionalizing and biological samples) and optical 
measurements. The results confirmed the capability of the RT-LPG biosensor to successfully 
monitor the presence of AmpC BL at a lower concentration and to obtain a sensitivity 
amplification of the device of a 2.96 factor. Also, the potential of the RT-LPG probe to 
specifically detect the β-lactams protein in complex matrices is reported. 
2. Methods 
2.1. Materials 
Ethanol (EtOH), isopropyl alcohol (IPA, analytical grade 99.7), double-distilled water 
(ddH2O), chloroform (CHCl3, analytical grade 99.9), atactic polystyrene (aPS, MW = 
280.000), poly(methylmethacrylate)-co-methacrylic acid (PMMA-co-MA, MW = 34.000), 
dextrose, aqueous ammonia (NH3 30% w/w), 1-ethyl-3-[3-
dimethylaminopropyl]carbodiimidehydro-chloride (EDC) and N-hydroxysuccinimide (NHS) 
were purchased from Sigma-Aldrich (Milan, Italy). Chloroform (CHCl3) and potassium 
hydroxide (KOH) were purchased by J.T. Baker. 5-Aminomethylbenzo[b]thiophene-2-yl-
boronic acid (BZD) were synthesized by reported procedure [4]. Recombinant AmpC BL was 
purified, and Escherichia Coli lysate solutions were prepared as reported below. 
2.2. Protein purification and preparation procedure 
AmpC BL of Pseudomonas aeruginosa was extracted from E. Coli BL21 (DE3) bacterial 
culture, carrying the pET9a_AmpC plasmid vector. The properly transforming bacterial cells, 
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were selected by Ampicillin antibiotic resistance and then inoculated into 5.0 mL of Luria-
Bertani (LB)-broth, at 37°C, 120 RPM, for 4 hours. The entire small-scale liquid culture was 
poured into 1.0 L of self-inducing growth medium and incubated at 37°C, 120 RPM, for 12 
hours. The entire cell suspension was centrifuged at 4°C, 4500 RPM, for 40 minutes, 
recovering the bacterial pellet into the assay buffer solution (20 mM NaH2PO4, 30 mM NaCl, 
pH 7.5). The cells were broken by sonication cycles (Sonopuls HD 2070, Elettrofor) and the 
obtained sample was centrifuged at 4°C, 12000 RPM, for 30 minutes. The supernatant was 
recovered and filtered by 0.80-0.45 µm syringe filters. The resulting lysate sample was loaded 
onto XK 16/20 affinity column, functionalized with 3-methylaminophenyl-boronic acid (3-
MAPB), previously equilibrated with the same assay buffer solution. AmpC target protein 
was purified using an automatic purifier system (AKTA Prime Instrument, Amersham 
Bioscience) and it was eluted by elution buffer (500 mM Boric Acid, 20 mM NaH2PO4, 30 
mM NaCl, pH 7.5). BL enzyme activity was checked in each elution fraction by 
spectrophotometric method employing Cephalothin as β-lactam-antibiotic substrate at final 
concentration of 100 µM. The most active fractions were pooled together, in order to have a 
final concentration of 1 mg/mL, as assessed by UV-scan assay. The purity grade of the 
purified protein sample was checked by SDS-page analysis (>> 95%). The protein sample 
was lyophilized and a proper protein-reconstitution protocol has been set up, in order to 
obtain AmpC protein solutions at fixed concentration for the next binding experiments. The 
so reconstituted AmpC BL was then added into the cell lysate samples obtaining a final 
calculated BL concentration equal to 3.65 µM [17]. 
2.3. AmpC BL kinetic assay 
The full kinetic profile of purified AmpC BL was evaluated measuring the experimental 
values of the parameters mainly describing the kinetic activity of the enzyme protein 
(catalytic constant kcat and substrates-affinity constant Km). The experimental results, for 
each parameter, were in agreement with the data reported by the scientific literature [22]. In 
order to assess the kinetic functionality of the purified AmpC protein, we have performed a 
kinetic assay by spectrophotometric method (DU-640 spectrophotometer, Beckman Coulter). 
The assay consists of monitoring the time-dependence β-lactam hydrolysis enzyme reaction, 
at the specific wavelength of the Cephalothin antibiotic substrate (265 nm), for a total time of 
300 seconds. The kinetic assay was performed at room temperature (RT), in a final total 
volume of 600 µL. The several reaction reagents were properly added as followed: 1) assay 
buffer solution to volume of 600 µL (20 mM NaH2PO4, 30 mM NaCl, pH 7.5); 2) AmpC 
enzyme at concentration of 0.115 µM; 3) Cephalothin β-lactam antibiotic substrate at final 
concentration value of 100 µM. The third step represents the rate-determining step (RDS), 
because the adding of antibiotic substrate causes the starting of the enzyme reaction. The 
resulting Vmax value equal to 0.235 µM/s, confirmed the acceptable kinetic rate of the AmpC 
enzyme under the considered experimental conditions. 
2.4. Enzymatic inhibition assay 
The capability of BZD compound for binding and inhibiting the kinetic activity of the AmpC 
enzyme, was evaluated by detecting the IC50 (the inhibitor’s concentration able to reduce by 
50% the enzyme activity of AmpC BL). The assay consists of evaluating, by 
spectrophotometric method at the specific Cephalothin absorption wavelength (265 nm) for 
300 seconds, the dose-dependence reduction of enzyme kinetic activity with increasing 
concentrations of inhibitor molecule. With this aim, the assay is performed at fixed value of 
enzyme and substrate concentration, varying the concentration of the inhibitor. The 
compound was first dissolved in dimethyl sulfoxide (DMSO) in order to obtain an initial 
concentration of 10 mM. First, an inhibition assay at two single concentration points (0.25 
and 0.50 µM), in duplicate, was performed to identify the optimal ligand concentrations range 
for the next IC50 assay. Based on the obtained inhibition data (19% and 41% respectively), the 
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ligand IC50 value was evaluated by testing six different concentrations (0-0.1-0.2-0.4-0.8-1.6 
µM) and using an enzyme and a substrate concentration of 0.115 µM and 100 µM, 
respectively. Each inhibitor concentration was analyzed in duplicate with a statistical 
significance (p-value < 0.005). Assuming a competitive inhibition for the BZD compound, 
like other boron-based non β-lactam inhibitors [23], it is possible to calculate the IC50 value 
from the plot 1/V vs [I] considering the general equation IC50 = {[(1/2Vmax/) – q]/m} [24]. In 
this way, the IC50 value for the BZD inhibitor was equal to 0.75 µM. In good approximation, 
regarding the competitive inhibitors, the IC50 is correlated to the inhibition constant value (Ki) 
using the Cheng-Prusoff relationship (IC50 = Ki [1 + ([S]/Km)]) [25]. The corresponding Ki 
value for the BZD compound (0.23 µM), was in agreement with the value previously reported 
in literature (0.26 µM) [4]. 
2.5 Preparation of reflection-type LPG probe and surface biofunctionalization 
The main fabrication steps for the realization of the RT-LPG are (i) the inscription of the 
grating in the optical fiber followed by the fiber cutting, (ii) the Ag reflecting layer (i.e. the 
mirror) integration on the fiber tip and (iii) the double layer (aPS and PMMA-co-MA) 
deposition on the RT-LPG surface. All steps were performed following the procedures 
reported in Ref. 17. 
The sensor surface biofunctionalization is composed of two steps: (i) the activation of the 
carboxylic groups by EDC/NHS reaction and (ii) the BZD ligand anchoring onto the RT-LPG 
biosensor surface. The activation of the carboxylic groups is made possible by a first 
immersion of the probe in 1.0 mL of clean ddH2O followed by addition of 0.5 mL of a freshly 
prepared EDC/NHS solution (0.05 M/0.03 M, 1:1 molar ratio) and by a final washing in 
ddH2O (30 min). Once the activation of the carboxylic groups is performed, the BZD 
anchoring can be achieved through the sequential immersion in: ddH2O (30 min), 3.38 mM 
BZD solution (60 min) and, again, ddH2O (30 min). To ensure the most possible coverage, 
the BZD anchoring procedure was repeated twice. The so functionalized RT-LPG probe was 
used for the following protein binding tests. 
2.6. Protein binding test 
On the BZD-functionalized RT-LPG, tests were performed using AmpC BL solutions at 
different increasing concentrations, in the range of 50-500 nM. The procedure consisted of 
sequential immersions of the probe in solutions [17] and for each AmpC concentration tested 
the steps are: (i) washing in ddH2O, (ii) immersion in AmpC solution, and (iii) washing in 
ddH2O. 
3. Results and discussion 
3.1 The new ligand (BZD) 
In this paper we used as probe BZD that has a different biological profile with respect to 3-
APBA studied in our previous work [17]. BZD is also able to inhibit the AmpC enzyme, but 
it is about 30 times more active with respect to 3-APBA [26,27]. This difference in Ki (0.26 
μM with respect to 7.3 µM) might lead to a different performance of the device upon the 
ligand attachment, worthy of being investigated. In principle, we expected that the higher 
affinity of BZD for AmpC could lead to a higher efficiency in capturing the enzyme (ligand-
protein complex formation) from the cytoplasmic environment, and to a higher specificity 
generating less background noise in the device detection signal. 
3.2 Design and development of the automated system for simultaneous multi-target 
clinical analyses 
As known, a typical molecule/protein detection test, involving a RT-LPG probe, requires the 
immersion of the transducer in a variety of solutions used to functionalize the surface of the 
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probe and reveal the concentration of the target analytes. These stages are interspersed by the 
immersion of the probe in several buffer solutions, depending on the specific kind of 
experiment. Therefore, it becomes essential to provide an automatic positioning system 
allowing the immersion and extraction of the sensor within the different liquid solutions. 
Another fundamental requirement is the ability to process more RT-LPG probes 
simultaneously, enabling the testing of different kind of solutions (e.g., detecting the presence 
of different classes of BL using distinct protocols of functionalization) at the same time, 
resulting in a higher throughput. In order to address these needs, we have designed and 
developed an automated system able to fully operate up to eight RT-LPG probes in specific 
protocols, by changing the solutions under test and performing optical measurements. 
The design of the system addresses two different requirements: i) it features a set of 
electrical and mechanical components concerning the movements required to change the 
solutions during the experiments; ii) it is provided with an optoelectronic unit related to the 
optical interrogation of the RT-LPG probes. The system has been designed using Solid Works 
(Dassault Systemes SolidWorks Corporation), a 3D mechanical CAD (computer-aided 
design) software. Figure 2 shows a conceptual scheme summarizing the main parts of the 
system. Essentially, a support (fiber holder) holds up eight optical fibers, in such a way that 
the terminal part of them (sensing tips) is disposed vertically, and parallel to the others. In this 
way, the sensitive end of each probe, namely the RT-LPG, is aligned with the centre of the 
cuvettes in which it will be immersed, avoiding any contacts with the walls of the cuvettes 
themselves. 
 
Fig. 2. Conceptual scheme summarizing the main parts of the system. 
The automatic change of the solutions is realized by translating a cuvette carousel 
sustaining a standard 96-well plate (providing a matrix of 12 × 8 cuvettes), through the 
control of two linear actuators along the horizontal (X) and vertical (Z) directions. Although 
different configurations could be considered, it is preferable to move only the cuvette 
carousel, keeping the fibre probes fixed during all the operations, avoiding any power 
fluctuations throughout the experiments. A customized optoelectronic processing unit collects 
the spectra of the eight RT-LPG probes. A PC software manages both the movements and the 
spectral interrogation, retrieving and elaborating the optical probes outputs. 
All the components have been integrated into a suitable enclosure, protecting all the 
delicate parts on its inside, including the RT-LPG probes, the 96-well plate, the linear 
actuators, the optical components and the electronic circuitry. A door provides access to the 
test chamber (see Fig. 3(a)), where it is possible: i) to mount the transducers, through a 
delicate but precise fixing, assisted by a small CMOS camera (HP Webcam HD 5210, HP 
Development Company, L.P., CA, USA) connected to the PC; ii) to fill the cuvettes with 
liquid solutions required by the protocol. The 96-well plate (available with different heights 
and volumes of hundreds of µL from Corning Enterprises, Corning, NY, USA) is held by a 
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plate moved by the vertical linear actuator (DL 20-45-ST-PH from Del-Tron Precision, Inc., 
CT, USA), which allows to immerse and withdraw the RT-LPG probes into the cuvettes. The 
vertical actuator is mounted on the horizontal one (BG 2602A-200P/A5K from Nippon 
Bearing Co., LTD, Japan), which moves along the X direction, translating with itself the 
vertical actuator and the 96-well plate. 
 
Fig. 3. (a) View of the manufactured automated system, showing the test chamber. (b) View of 
the optoelectronic interrogation unit and electronic circuits hosted on the side panel (the 
enclosure has been removed). 
The optoelectronic interrogation unit, the electronic circuits for the control of the entire 
system, the connection with the host PC and the power supply are mounted on a side panel, as 
shown in Fig. 3(b) (where the enclosure has been removed). The optoelectronic interrogation 
unit is schematically shown in Fig. 4. Basically, a light source (SLED, Superluminescent 
Light Emitting Diode, peak wavelength = 1575.98 nm) illuminates the RT-LPG probes, 
whose reflected spectra are sent every 45 seconds to a spectrometer (WaveCaptureTM 
Spectrometer, BaySpec, Inc, CA, USA), characterized by a wavelength range of 80 nm 
(1530-1610 nm), an absolute wavelength accuracy of ± 35 pm and a wavelength repeatability 
of 5 pm. 
 
Fig. 4. A scheme of the architecture of the optoelectronic interrogation unit. 
An optical isolator (ISO) is inserted just after the light source, allowing the transmission 
of light in only one direction, avoiding undesirable feedback into the source. A variable 
optical attenuator (VOA) ensures proper control of the power intensity emitted by the source 
preventing the saturation of the spectrum. A 1x8 optical switch is used to select and 
interrogate one at a time each RT-LPG probe. In order to obtain normalized spectra (C), a 2x2 
coupler and a 2x1 switch are used. In particular, we first acquired the reference spectrum of 
the light source itself (A, blue path in Fig. 4), then we acquired the spectra reflected by the 
RT-LPG probes (B, red path in Fig. 4). Once the spectra have been acquired, a software 
(Sense 20/20, BaySpec, Inc, CA, USA) adequately customized performs a normalization 
following the equation shown below Eq. (1): 
      10C 10 Log B / A .                (1) 
Then the spectra are filtered and elaborated providing the central resonance wavelengths (λc) 
of each spectrum, enabling a continuous and real time monitoring of the interaction kinetics 
of the biological molecules on the RT-LPG surface. Moreover, to perform completely 
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automated biological tests, the customized software allows to execute automated scripts, 
including the commands for the translation stages and acquisition of the RT-LPG spectra. 
3.3 Experimental results 
Since boronic acid-derivatives are high affinity inhibitors of BLs [28–31], in our previous 
work the well-known AmpC inhibitor 3-APBA was immobilized on the RT-LPG surface, and 
used to bind and recognize AmpC in both purified solutions and complex biological samples, 
at the very low concentration of 100 nM. These encouraging results induced us to verify, and 
possibly improve, the capability of the RT-LPG biosensor to detect AmpC presence using a 
different boronic-acid derivative. The BZD ligand was selected according to the following 
properties: the predicted orientation within the enzyme binding site (as described below) and 
the high affinity towards the target AmpC BL [17]. Furthermore, BZD fulfills the 
bioanchoring requirement, having a primary amine able to covalently bind the ester groups 
that functionalize the double-coated RT-LPG surface. 
3.3.1 Inhibition activity of boronic acid against AmpC BL 
The typical reactivity of the boronic group is due to its empty orbitals on the boron atom and 
its susceptibility to react with nucleophiles as the active site serine of BLs. The diols 
formation due to dehydration reaction with sugar hydroxyls gives rapidly reversible diols and 
therefore these compounds are used for the recognition of sugars derivatives in analytical 
device [32,33]. The BLs inhibition mechanism of phenyl and benzothiophene boronic acid 
derivatives is based on the formation of a reversible covalent acyl-enzime intermediate with 
the BL enzyme [17]. These compounds, in fact, mimic the antibiotic transition state, with the 
boronic group replacing the β-lactam ring and interacting with the catalytic serine through the 
formation of a similar tetrahedral intermediate (Fig. 5(a)). A necessary condition for the 
interaction and recognition of BLs is that the boronic group is free to interact with the 
hydroxyl moiety of the enzyme catalytic site represented by a serine molecule. The boronic 
group represents the chemical recognition element fundamental for the covalent bond 
formation. The ligand has to bear a primary amino group for anchoring to the RT-LPG probe. 
(a)
(b) (c)
(d)
 
Fig. 5. (a) Action mechanism of a generic boronic acid inhibitor. (b-d) Possible orientation of 
BZD in AmpC binding site (derived by AmpC-BZD complex; PDB code 2i72 [35]). Overall 
view of the BZD-AmpC BL complex (b) and (c). The protein is represented as surface and 
cartoons, respectively, the ligand in capped sticks. (d) Binding site close-up. BZD and the 
residues lining the pocket are shown in capped sticks. Hydrogen bonds formed by the ligand 
with the surrounding residues are reported as black dashed lines. Crucial residues are labelled. 
The amino group involved in the RT-LPG covalent anchoring is highlighted by the red circle. 
The binding mode of BZD in AmpC binding site is reported in Fig. 5(b)-5(d). The BZD-
AmpC complex was modelled on the x-ray AmpC-5-diformylaminomethyl-
benzo[b]thiophen-2-boronic acid complex (PDB code 2i72) [34], upon deletion of the 
diformyl moiety. The ligand is able to covalently bind to the catalytic Ser64 through the 
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boronic group and to form hydrogen bonds with the same Ser64, the Ala318 backbone, and 
the Tyr150 side chain, thus stabilizing the complex formation. The amino group shows a 
relevant accessible surface area and is not directly involved in any contact with the 
surrounding residues (while 3-APBA forms a hydrogen bond with Asn346 [34]. The space 
availability around the primary amine suggests that the anchoring process, involving the 
formation of a covalent bond between the amino group and the ester moieties on the RT-LPG 
surface, would not dramatically affect the structural organization of the AmpC-BZD complex. 
Nevertheless, the immobilization of the ligand on the fibre surface and the consequent 
reduction of the ligand degrees of freedom, the presence of an additional amidic bond, and the 
loss of the primary amino function might reasonably change the value of the estimated Ki for 
the protein-ligand complex in solution. 
3.3.2. Biofunctionalization of RT-LPG 
Among several methods generally used for the biofunctionalization of probes on solid 
surface, an attractive strategy is represented by the covalent attachment of ligands causing an 
improvement in terms of reliability, selectivity and sustainability [35]. The adopted standard 
procedure consists of the preparation of a succinimidyl ester (-COOSuc)-terminated surface 
layer through the reaction with N-hydroxysuccinimide (NHS), in the presence of a water-
soluble carbodiimide as N-ethyl-N’-(3-dimethylaminopropyl)-carbodiimide (EDC) or other 
similar coupling agents [36,37]. In particular, the activated amine-reactive esters, easily form 
covalent bonds with the BZD ligand. Hence, the binding of BL protein can occur due to the 
affinity for the ligand on the surface. 
A generic BZD binding experiment consists of a first activation of the carboxyl groups on 
the sensor surface by treatment with EDC/NHS and by the successive reaction with BZD. In 
Fig. 6(a) the typical real time sensorgram, reporting the time variation of the probe resonance 
wavelength obtained during the biofunctionalization of the RT-LPG transducer is showed. 
The RT-LPG was immersed in 1.0 mL of ddH2O (step I) to acclimate the sensor surface and 
rinsed until the stabilization of the optical signal (for about 45 min) and, subsequently, 0.5 mL 
of EDC/NHS solution were added dropwise (step II), to reach respectively 0.05/0.03 M (1:1) 
concentrations in the final solution. Then, the sensor was rinsed in 1.5 mL of clean ddH2O 
(step III), for about 30 min, to remove the reagent non-specifically bound to the sensor 
surface. The RT-LPG resonance wavelength shift recorded between steps III and I (ΔλIII-I), 
and due to the activation of the carboxylic groups on the PMMA-co-MA surface, was about 
2.0 nm. The so activated sensor surface was then immersed in 1.5 mL of BZD solution (step 
IV) and the kinetic of covalent binding was monitored for a reasonable time of 60 min 
followed by washing in clean ddH2O (step V). The ligand was used in excess to guarantee the 
highest possible surface coverage of carboxyl groups on PMMA-co-MA layer per immersion 
step. Between the two washing steps (steps V and III), a blue shift ΔλV-III = 1.2 nm was 
observed for the optical signal indicating the BZD attachment to the surface. The ligand 
binding was repeated (VI and VII) in the same conditions to ensure a complete coverage of 
all the surface functionalized groups. The wavelength shifts recorded (steps VII and V) were 
ΔλVII-V = 1.8 nm. As expected, the interaction of BZD with the sensor surface- induces a 
decrease of the output signal, which can be explained with an increase of the thickness of the 
deposited biolayer. 
3.3.3. AmpC BL detection 
The optical biosensor capability of binding AmpC was subsequently tested on a wide range of 
protein concentrations (50 nM - 5.0 μM). Figure 6(b) reports the real time sensorgram 
obtained with three increasing AmpC concentrations of 50, 100 and 300 nM, respectively. 
The BZD-coated RT-LPG was immersed in clean ddH2O (VIII) for a first acclimation. After 
the stabilization of the optical signal, the RT-LPG probe was extracted and successively 
immersed in an AmpC BL solution at the low concentration of 50 nM (IX), until the 
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stabilization of the optical signal (about 60 min). The molecules non-specifically bound on 
the sensor surface were removed by washing the probe in ddH2O (X). The wavelength shift 
recorded between the two washings (steps X and VIII) was equal to 0.45 nm. These last 
steps, i.e. the immersion in a fresh protein solution followed by the washing in ddH2O, were 
repeated in the same conditions using higher AmpC concentrations, that is, 100 and 300 nM 
(steps XI-XIV). The measured wavelength shifts (between the washings before and after the 
AmpC binding) turned out to be 0.75 and 1.95 nm, respectively. Then, the saturation grade 
of the biofunctionalized surface of the RT-LPG biosensor, also at higher AmpC 
concentrations (0.5, 1.0 and 5.0 µM) were explored. In these cases, the ΔλAmpC-binding resulted, 
respectively, 2.40, 0.50 and 0.15 nm. In Fig. 6(c) is reported a schematic representation of 
the RT-LPG coated with aPS and PMMA-co-MA layers after AmpC BL binding 
experiments. 
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Fig. 6. (a) RT-LPG sensorgram during the biofunctionalization phase. (b) RT-LPG sensorgram 
during the AmpC β-lactamase binding experiments. (c) Schematic representation of the RT-
LPG coated with aPS and PMMA-co-MA layers for AmpC β-lactamase binding experiments. 
It is worth mentioning that the time actually needed for the protein binding test comprises 
only the three steps reported in section 2.6: (i) washing in ddH2O, (ii) immersion in AmpC 
solution, and (iii) washing in ddH2O, while the previous steps can be considered as 
preparation steps, not affecting the effective time required by the protein detection. Therefore, 
assuming the LPG sensor ready for the detection, the total time required for the analysis using 
the proposed LPG probes is about 150-200 min. This quite long response time exhibited by 
the LPG probe is mainly due to the uptake time required to stabilize the coated LPG when 
used in batch tests. Indeed, every time the LPG probe is extracted and submerged into a new 
solution, a sort of acclimatization of the polymer layer is observed as a fast red wavelength 
shift [14–17] (lasting ~30 min) before the RT-LPG biosensor response reaches a steady state 
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value. However, we wish to point out that the integration of the RT-LPG platform in a 
suitable optofluidic system, enabling its operation in flow condition, would enable to avoid 
the LPGs extraction/submersion into the aqueous solutions and, consequently, the uptake 
process, leading to a significant reduction of the biosensor response time [38]. A correct 
analysis of the recorded measures requires to consider the following issue: although the 
fabrication process is robust and repeatable, a normalization procedure is needed to account 
for the even tiny discrepancy in the SRI sensitivities of different RT-LPG probes (mainly due 
to the LPG fabrication tolerances or to slightly different aPS or PMMA-co-MA overlay 
thickness obtained in the different devices). To this aim, we performed a normalization 
between the wavelength shift (Δλair-water) occurred in two medium with different refractive 
index (SRIair = 1 and SRIwater = 1.333) and the wavelength shift occurred upon PMMA-co-
MA layer deposition (ΔλPMMA). Then, we defined an observable as: 
 air water air water PMMAO /     
The normalized value (Oair-water) for the probes used in the experiments is very similar (Oair-
water mean value is 6.5 with a RSD of 6%) and guarantees good robustness and reliability. In 
line with this argument, considering that the ligand or protein binding has been calculated as 
the wavelength shift after and before washing in water, we defined a new observable as: 
 C PMMAO /     
where, ΔλC corresponds to the wavelength shift after and before washing in water. This 
method allows the comparison of the results obtained with different RT-LPG probes, and 
built up a unique biosensor AmpC dose-response curve (i.e. the biosensor calibration curve). 
The obtained curve (orange curve in Fig. 7) presents a linear behavior at low AmpC 
concentrations (50 - 300 nM), while it reaches the saturation for higher protein 
concentrations. 
To monitor the non-specific protein binding, a blank test has been also performed using a 
coated RT-LPG previously treated with only EDC/NHS (without anchoring the BZD ligand). 
The purified AmpC was tested using the same procedure and increasing the protein 
concentration. No sensor response was registered at low concentrations, while a slight blue 
shift (Δλ = 0.08 nm) was measured starting from 1.5 µM concentration (cyan curve in Fig. 
7), which, however, turned out to be more than seven times lower with respect to the response 
obtained with the biofunctionalized device. The results confirmed the high affinity of the 
BZD ligand and, overall, the potentiality of the proposed bioprobe. 
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Fig. 7. Characteristic curves (O vs. AmpC BL cumulative concentrations) of the RT-LPG 
device obtained by binding experiments with purified AmpC (orange curve) and negative 
blank test using not functionalized probe (cyan curve). The error bars refer to the standard 
deviation calculated by considering the results obtained by repeating 3 times the experiment 
with the same concentration. 
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In order to roughly estimate the limit of detection (LOD) of the BZD-functionalized RT-
LPG biosensor, we determined the sensitivity against AmpC BL, calculated as the derivative 
of the characteristic curve (O vs. AmpC concentration) in the linear region (50-300 nM): 
 1
AmpC BZD AmpC BZDS O / C 1.449

          (1) 
Considering that the minimum observable Omin can be expressed as: 
 min min PMMAO /    (2) 
where Δλmin is the minimum wavelength variation (set by the interrogation unit) and equal to 
35 pm, the LOD for the probe functionalized with BZD resulted: 
 AmpC BZD min AmpC BZDLOD O / S 6 nM        
3.3.4. AmpC BL detection in bacterial lysate solution 
Once verified the effectiveness of the BZD-coated RT-LPG biosensor in purified AmpC 
samples in PBS buffer solutions, we were interested into detection of BL at low 
concentrations - which are more important in biomedical field - in more complex biological 
models. Hence, further experiments were carried out to investigate the bioprobe capability to 
detect the presence of protein in bacterial lysate samples, in which AmpC was previously 
added. For this purpose, E. Coli lysates were used with AmpC at 50 nM and 100 nM 
concentrations. A representative sensorgram obtained during the tests in “lysate” is reported 
in Fig. 8(a). Similarly to the previously reported procedure, the biofunctionalized RT-LPG 
probe was first acclimated in clean ddH2O (VIII’), and successively immersed for about 60 
minutes in the lysate sample (IX’) containing an AmpC BL concentration of 50 nM. Finally, 
the probe was washed in clean ddH2O (X’) to remove the molecules non-specifically bound to 
the sensor surface. The RT-LPG probe was also tested with a further, slightly higher, AmpC 
BL concentration of 100 nM (XI’), followed by rinsing in ddH2O for about 60 minutes 
(XII’). Although the low BLs concentrations used in this test (i.e. 50 nM and 100 nM), the 
wavelength shifts (ΔλC_Lys) recorded by our device between X’ and VIII’ steps, and between 
X’ and XII’ steps resulted to be as high as 0.5 nm and 1.0 nm, respectively. The calculated 
values of the observable O corresponding to AmpC concentrations detected in complex lysate 
(violet stars) resulted to be in perfect agreement with the one obtained for purified AmpC in 
PBS buffer solutions (orange curve in Fig. 8(b), 8(c)). Control experiments to verify the 
possible effect of the complex matrix in the detection of lower protein concentrations were 
also performed. In particular, a RT-LPG probe previously treated with only EDC/NHS, 
(without anchoring the BZD ligand) was tested in a lysate solution. 
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Fig. 8. (a) Reflection-type LPG sensorgram reporting the central wavelength shift of 6th 
cladding mode attenuation band during the AmpC BL binding for lysate solutions containing 
different protein concentration. (b) Characteristic curves (O vs. AmpC BL cumulative 
concentrations) of the RT-LPG device obtained for binding experiments with purified AmpC 
(orange curve) in PBS buffer solution and AmpC in complex lysate (violet stars), negative 
blank test (i.e. using not functionalized probes) in PBS buffer solution (cyan curve), and 
control test using complex lysate without BZD (red star). The error bars refer to the standard 
deviation calculated by considering the results obtained by repeating 3 times the experiment 
with the same concentration. (c) Inset showing a magnification of the results obtained at low 
concentrations. 
The results reported as red star in Fig. 8(b) showed a very small response both in terms of 
resonance wavelength variation (ΔλLys_blank  0.35 nm) and observable (O  0.058). The 
observable value resulted to be less than half the value obtained when the lysate solution 
contained 50 nM of AmpC BL, thus confirming once more the capability of our device to 
correctly detect the target protein also in complex media. 
As mentioned at beginning of the paper, our first experiments on RT-LPG biosensor were 
performed using 3-APBA, a commercial product previously applied for AmpC BL detection 
in colorimetric assays. 3-APBA, due to low cost and low micromolar affinity towards β-
lactamase, represented the best option for our first experiments, necessary to test the proof of 
principle related to RT-LPG biosensor based on small molecule ligands as bio-receptor. Non-
commercial ligands with different chemical and biological features were then selected to 
improve the system applicability and enhance the innovation aspects of the detection system. 
BZD was selected among boronic acids due to its about 30-fold higher affinity towords 
AmpC with respect to the previously tested 3-APBA, with Ki being 0.26 and 7.3 µM, 
respectively. To verify the RT-LPG biosensor performance improvement, we compared in 
Fig. 8(b) the calibration curves with those obtained by using the 3-APBA-functionalized RT-
LPG, and observed that: i) the presence (common to both biosensors typology) of a linear 
region in a low concentration range (up to 300-500 nM) and a saturation region where a 
plateau value (over about 3.0 µM) was achieved; ii) the sensitivity of the RT-LPG probes 
functionalized with the BZD (i.e. the slope of the calibration curve in the linear region) is 
much higher (1.449 μM1) with respect to that provided by the 3-APBA-based device (0.486 
μM1), and this results in a reduction of the LOD of the former device of a factor higher than 
three (6 nM instead of 20 nM); iii) both biosensors exhibit a saturation regime in 
correspondence of an O value of about 0.8. Overall, the results here reported confirm the 
potentiality of the RT-LPG fiber optic biosensing platforms, which enables to correctly detect 
AmpC BL at low nM concentration, even in complex biological matrix as bacterial lysate. 
4. Conclusions 
We reported here a valuable proof of principle for the development of fully automatic optical 
assays for the real time monitoring of AmpC BLs, one of the most important source of 
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resistance to BL antibiotics expressed by drug resistant bacteria. Highly sensitive fibre optic 
optrodes based on LPG working in transition mode and operating in reflection were selected 
as enabling technologies for the automatic assay. As probes, boronic acids were selected in 
light of their BL inhibition capability and among them, BZD was judiciously identified to be 
covalently bound to the sensor surface due to its enhanced affinity for AmpC BL with respect 
to the previously used 3-APBA. Furthermore, the selected probe presents a favorable 
orientation within the protein binding site allowing a better anchoring reaction and, thus, a 
more effective probe functionalization. In order to provide an engineered platform for 
automatic optical assays, a dedicated opto-bio-lab system has been developed including an 
automatic positioning system able to simultaneously manipulate eight RT-LPG probes during 
all the specific phases of the assay. The system also includes the optical readout for the real 
time monitoring of the optical fibre biosensors though spectral analysis. A wide set of AmpC 
BL binding tests was performed using RT-LPGs functionalized with BZD on samples 
containing the purified target protein at increasing concentrations in the 50 nM - 5.0 μM 
range. Overall, the reported results clearly demonstrated the capability of the developed 
optical biosensor to correctly perform the label-free detection of AmpC BLs, both in simple 
and complex biological samples. Dose-dependent experiments showed that the sensor 
response is linearly dependent to the protein concentrations in the low-concentration range. 
The results here obtained for BZD demonstrated a LOD of about 6 nM, three times lower 
than that obtained using the same RT-LPG platform functionalized with a lower affinity 
ligand (3-APBA). 
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